{"product_id":"resveratrol-600mg-60-capsules-30-day-supply","title":"Resveratrol Complex Capsules","description":"\u003cp\u003e\u003cstrong\u003e600 mg of trans-resveratrol per capsule\u003c\/strong\u003e — the SIRT1-activating polyphenol that anchors the canonical NMN + resveratrol longevity stack. ≥98% HPLC-verified trans-anomer from \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e root extract, vegan capsule, no fillers, no proprietary blends. Stack-grade dose, not a label-claim dose.\u003c\/p\u003e\n\n\u003ch2\u003eThe 30-second answer\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe polyphenol that put sirtuins on the longevity map.\u003c\/strong\u003e Howitz 2003 \u003cem\u003eNature\u003c\/em\u003e identified resveratrol as the most potent natural sirtuin-activating compound (STAC) ever screened; Baur 2006 \u003cem\u003eNature\u003c\/em\u003e showed it extended lifespan in calorically-stressed mice; Hubbard 2013 \u003cem\u003eScience\u003c\/em\u003e solved the SIRT1 allosteric crystal structure. Two decades and 13,000+ PubMed hits in, trans-resveratrol remains the canonical SIRT1 activator.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOne capsule, daily, with the largest fat-containing meal.\u003c\/strong\u003e Resveratrol is fat-soluble — fasted dosing throws away most of the pill. Pair with breakfast (eggs, avocado, fatty fish, olive oil) or lunch.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBest paired with \u003ca href=\"\/he\/products\/pure-nmn-500mg-60-capsules-30-day-supply\"\u003eNMN 500 mg\u003c\/a\u003e or \u003ca href=\"\/he\/products\/nmn-1000mg-pure-focus-formula-cellular-rejuvenation\"\u003eNMN 1000 mg\u003c\/a\u003e.\u003c\/strong\u003e NMN raises NAD+ substrate; resveratrol activates the SIRT1\/SIRT3 enzymes that \u003cem\u003euse\u003c\/em\u003e that NAD+. Substrate + activator. Get both at -10% as the \u003ca href=\"\/he\/products\/longevity-stack-bundle-nmn-500mg-resveratrol-600mg\"\u003eLongevity Stack Bundle\u003c\/a\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e600 mg is the stack-grade dose.\u003c\/strong\u003e 100–250 mg is where the \"resveratrol doesn't work in humans\" meta-analyses concentrate; 500–1000 mg\/day is where the cardiometabolic and SIRT1 data live (Tomé-Carneiro 2012\/2013, Bhatt 2012, Movahed 2013, Pollack 2017).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e≥98% HPLC trans-resveratrol.\u003c\/strong\u003e The bioactive anomer — not the cis-isomer UV-degradation product cheap brands ship. Per-batch third-party COA, heavy-metals\/microbial\/residual-solvents panel, vegan HPMC capsule, no titanium dioxide, no magnesium stearate, no rice-flour bulker.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWhy resveratrol still anchors a serious longevity stack — even after the noise\u003c\/h2\u003e\n\u003cp\u003eIf you only read the headlines, you'd think resveratrol got debunked. It didn't. What got debunked was the \u003cem\u003e1 mg of resveratrol in a glass of red wine\u003c\/em\u003e story — Smoliga 2011 (\u003cem\u003eMol Nutr Food Res\u003c\/em\u003e) showed you'd need ~1,500 bottles a day to hit the doses tested in the original Sinclair-lab mouse work. The science on the \u003cem\u003emolecule itself\u003c\/em\u003e kept moving in the right direction.\u003c\/p\u003e\n\u003cp\u003eThe López-Otín 2013 (\u003cem\u003eCell\u003c\/em\u003e) and updated 2023 hallmarks-of-aging frameworks list \u003cstrong\u003ederegulated nutrient sensing\u003c\/strong\u003e, \u003cstrong\u003emitochondrial dysfunction\u003c\/strong\u003e, \u003cstrong\u003echronic inflammation\u003c\/strong\u003e, and \u003cstrong\u003ecellular senescence\u003c\/strong\u003e among the twelve hallmarks. Resveratrol hits all four:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSirtuin activation (SIRT1, SIRT3)\u003c\/strong\u003e — the deacetylase axis that converts NAD+ into longevity-relevant outputs (PGC-1α, FOXO3a, p53, eNOS deacetylation).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAMPK activation\u003c\/strong\u003e — the same fuel-sensor pathway hit by metformin, berberine, and exercise (Park 2012, \u003cem\u003eCell\u003c\/em\u003e).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNF-κB suppression \/ inflammaging\u003c\/strong\u003e — inhibits IKK, stabilizes IκB, dampens p65 nuclear translocation (Csiszar 2008).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEndothelial protection\u003c\/strong\u003e — upregulates eNOS expression and activity (Wallerath 2002, \u003cem\u003eCirculation\u003c\/em\u003e); Tomé-Carneiro 2013 showed 350 mg\/day for 12 months reduced oxidized LDL by 20% in CHD patients \u003cem\u003ealready on statins\u003c\/em\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eNone of this requires resveratrol to be a magic pill. It just has to be the polyphenol with the strongest, longest-validated sirtuin-and-AMPK story across the most diverse organism panel — which it is.\u003c\/p\u003e\n\n\u003ch2\u003eMechanism — what resveratrol actually does inside the cell\u003c\/h2\u003e\n\n\u003ch3\u003e1. SIRT1 allosteric activation (the NMN partner)\u003c\/h3\u003e\n\u003cp\u003eSIRT1 is the most-studied of the seven mammalian sirtuins. It's a class-III deacetylase, meaning it consumes NAD+ as a co-substrate to remove acetyl groups from longevity-relevant substrates: \u003cstrong\u003ePGC-1α\u003c\/strong\u003e (mitochondrial biogenesis), \u003cstrong\u003eFOXO3a\u003c\/strong\u003e (stress resistance, antioxidant gene expression), \u003cstrong\u003ep53\u003c\/strong\u003e (apoptosis tone), \u003cstrong\u003eeNOS\u003c\/strong\u003e (vasodilation), \u003cstrong\u003eNF-κB p65\u003c\/strong\u003e (inflammation suppression), and the \u003cstrong\u003ehistone H3K9\/H4K16\u003c\/strong\u003e marks that gate the inflammatory transcriptome.\u003c\/p\u003e\n\u003cp\u003eWithout enough NAD+, SIRT1 stalls. Without an allosteric activator, SIRT1 runs at baseline. Resveratrol covers the second half. \u003cstrong\u003eHubbard 2013\u003c\/strong\u003e (\u003cem\u003eScience\u003c\/em\u003e) crystallized the SIRT1 N-terminal allosteric domain and showed resveratrol binds at a defined activator pocket, increasing SIRT1 activity toward acetylated substrates by up to 8-fold for substrates carrying hydrophobic recognition motifs. This resolved the earlier \"is the activation real or a fluorophore artifact?\" debate cleanly in resveratrol's favor.\u003c\/p\u003e\n\u003cp\u003eThis is the mechanistic argument for stacking \u003cstrong\u003eNMN (substrate) + resveratrol (activator)\u003c\/strong\u003e. NMN raises the NAD+ floor; resveratrol pushes the SIRT1 enzyme that uses it. Either alone is meaningfully under-leveraged; together they multiply.\u003c\/p\u003e\n\n\u003ch3\u003e2. SIRT3 and the mitochondrial deacetylase axis\u003c\/h3\u003e\n\u003cp\u003eSIRT3 is the major mitochondrial sirtuin and deacetylates ~65% of all mitochondrial-matrix lysine-acetyl marks. Its substrates include \u003cstrong\u003eSOD2\u003c\/strong\u003e (the manganese superoxide dismutase that scavenges mitochondrial ROS), \u003cstrong\u003eOPA1\u003c\/strong\u003e (mitochondrial fusion), and core ETC components. Resveratrol upregulates SIRT3 transcription and protein levels via PGC-1α-driven nuclear-respiratory-factor signaling — the same loop AMPK feeds into. Functionally, this is the leg behind resveratrol's mitochondrial-biogenesis signal in muscle (Lagouge 2006, \u003cem\u003eCell\u003c\/em\u003e) and the SOD2-mediated antioxidant signal that reduces mitochondrial-derived 8-oxo-dG damage in aging tissue.\u003c\/p\u003e\n\n\u003ch3\u003e3. AMPK activation (the metabolic fuel-sensor)\u003c\/h3\u003e\n\u003cp\u003eIndependent of sirtuins, resveratrol activates AMPK by inhibiting mitochondrial F1F0-ATP synthase (Park 2012, \u003cem\u003eCell\u003c\/em\u003e). Falling cellular ATP raises the AMP:ATP ratio, which is the upstream nudge AMPK senses. Activated AMPK then:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003ePhosphorylates and inactivates \u003cstrong\u003eACC\u003c\/strong\u003e (acetyl-CoA carboxylase) → lipid β-oxidation up.\u003c\/li\u003e\n  \u003cli\u003ePhosphorylates and inhibits \u003cstrong\u003emTORC1\u003c\/strong\u003e via TSC2 → catabolic autophagy up, anabolic protein synthesis down.\u003c\/li\u003e\n  \u003cli\u003ePhosphorylates \u003cstrong\u003ePGC-1α\u003c\/strong\u003e at Thr177\/Ser538 → mitochondrial biogenesis up, in concert with the SIRT1-deacetylation hit at the same protein.\u003c\/li\u003e\n  \u003cli\u003eTranslocates \u003cstrong\u003eGLUT4\u003c\/strong\u003e to muscle membrane → insulin-independent glucose uptake.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis is why the cardiometabolic trial signal for resveratrol is strongest in patients with insulin resistance, established CHD, or metabolic syndrome — the AMPK leg pulls weight even when the sirtuin leg is debated. It's also why resveratrol stacks cleanly with metformin and berberine: three different upstream inputs into the same fuel-sensor.\u003c\/p\u003e\n\n\u003ch3\u003e4. NF-κB suppression (the inflammaging dampener)\u003c\/h3\u003e\n\u003cp\u003eNF-κB is the transcription-factor central node behind senescent-cell SASP secretion, chronic CRP elevation, and most age-associated inflammatory tone. The López-Otín 2023 hallmarks paper added \"chronic inflammation\" as a standalone hallmark for exactly this reason. Resveratrol inhibits NF-κB activation at multiple steps:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIKK suppression\u003c\/strong\u003e — blocks the kinase complex that phosphorylates IκB.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIκBα stabilization\u003c\/strong\u003e — keeps the inhibitor bound to NF-κB longer.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ep65 nuclear-translocation block\u003c\/strong\u003e — even if some NF-κB escapes, less of it reaches DNA.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSIRT1-mediated p65 deacetylation\u003c\/strong\u003e — Lys310 deacetylation reduces NF-κB transactivation (Yeung 2004, \u003cem\u003eEMBO J\u003c\/em\u003e).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eCsiszar 2008 (\u003cem\u003eMech Ageing Dev\u003c\/em\u003e) demonstrated this in human coronary arterial endothelial cells; the effect is reproduced across hepatocytes, macrophages, and chondrocytes. This dovetails with the senolytic + NF-κB-suppression strategy: senolytics (Quercetin, Fisetin) clear senescent cells; resveratrol dampens the inflammatory tone the surviving cells secrete.\u003c\/p\u003e\n\n\u003ch3\u003e5. Endothelial \/ eNOS upregulation\u003c\/h3\u003e\n\u003cp\u003eWallerath 2002 (\u003cem\u003eCirculation\u003c\/em\u003e) showed resveratrol upregulates endothelial nitric oxide synthase (eNOS) at both transcriptional and post-translational levels. eNOS-derived NO is the master vasodilator and a key brake on platelet aggregation and leukocyte adhesion to the endothelium. The signal is dose-dependent and clinically translates: Tomé-Carneiro's Spanish CHD-cohort series (2012\/2013) showed grape-extract resveratrol (350 mg\/day for 6–12 months) improved flow-mediated dilation, reduced oxidized LDL, and shifted multiple inflammatory apolipoproteins, in patients \u003cem\u003ealready optimized on statins\u003c\/em\u003e.\u003c\/p\u003e\n\u003cp\u003eThis is part of why resveratrol kept its seat at the table after the \"French paradox\" framing aged badly — the molecular eNOS \/ NF-κB \/ SIRT1 mechanisms hold up even when the \"red wine prevents heart disease\" narrative doesn't.\u003c\/p\u003e\n\n\u003ch3\u003e6. Autophagy and the mTOR brake\u003c\/h3\u003e\n\u003cp\u003eThrough both AMPK activation and direct ULK1 phosphorylation, resveratrol induces macroautophagy — the cellular self-clearance program that clears damaged organelles, aggregated proteins, and dysfunctional mitochondria (mitophagy via PINK1\/Parkin). Pietrocola 2017 showed resveratrol triggers an autophagic signature in skeletal muscle that is mechanistically distinct from the spermidine-driven EP300 inhibition route, meaning the two stack additively. This is the leg behind the proteostasis-restoration argument for resveratrol — stacked with \u003ca href=\"\/he\/products\/spermidine-10mg-60-capsules-30-day-supply\"\u003espermidine\u003c\/a\u003e, you cover both major upstream autophagy switches.\u003c\/p\u003e\n\n\u003ch2\u003eThe trans-anomer — what \"≥98% trans-resveratrol\" actually means\u003c\/h2\u003e\n\u003cp\u003eResveratrol exists as two stereoisomers:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003etrans-resveratrol\u003c\/strong\u003e — the bioactive form. Every clinical trial measured this. Every SIRT1, AMPK, NF-κB, and eNOS mechanism documented above is trans-resveratrol's signature. This is the molecule the Sinclair lab tested, the molecule Tomé-Carneiro dosed, the molecule Hubbard crystallized.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ecis-resveratrol\u003c\/strong\u003e — a UV-degradation product. The double bond in the stilbene core photoisomerizes from trans to cis under exposure to ultraviolet light, oxygen, and heat. Cis-resveratrol has dramatically reduced SIRT1 binding affinity and minimal in-vivo activity in published comparisons.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eCheap resveratrol products mix them — and because cis-resveratrol can't be distinguished from trans by simple UV-Vis spectrophotometry (the cheap industry-standard assay), label claims that don't specify HPLC are often inflated by cis-isomer drift that occurred during storage, processing, or shipping. \u003cstrong\u003e≥98% HPLC trans-resveratrol means each batch is run on high-pressure liquid chromatography with diode-array detection at 308 nm — the assay that actually separates the two anomers.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe other 2% is residual \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e polyphenols (emodin, polydatin, piceid) at trace level, not cis-isomer drift. This is the molecular-grade material, not the food-grade material.\u003c\/p\u003e\n\n\u003ch2\u003eWhy \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e (Japanese knotweed)\u003c\/h2\u003e\n\u003cp\u003eTrans-resveratrol can be extracted from grape skins, peanut hulls, or \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e (Japanese knotweed) root. The Sinclair-lab work, the Tomé-Carneiro Spanish CHD trials, and the bulk of the human cardiometabolic literature all use \u003cem\u003eP. cuspidatum\u003c\/em\u003e for one reason: \u003cstrong\u003enatural concentration\u003c\/strong\u003e. Knotweed root contains 2–5% trans-resveratrol by dry weight, versus 0.001–0.01% in grape skin. That means knotweed extract reaches ≥98% HPLC purity through standard solvent partitioning; grape-skin extract requires aggressive chromatographic purification that often leaves residual matrix polyphenols and pesticide residues.\u003c\/p\u003e\n\u003cp\u003eThis product uses \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e root extract, ethanol\/water partitioned, recrystallized, ≥98% HPLC trans-resveratrol. Same source class as the trial materials.\u003c\/p\u003e\n\n\u003ch2\u003eClinical evidence — the trials that anchor 600 mg\u003c\/h2\u003e\n\u003cp\u003eThe \"resveratrol works \/ doesn't work\" debate gets cleaner once you stratify by dose, formulation, and population. Here is the evidence we anchor 600 mg on.\u003c\/p\u003e\n\n\u003ch3\u003eCardiometabolic — the strongest signal\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTomé-Carneiro 2012\u003c\/strong\u003e (\u003cem\u003eAm J Cardiol\u003c\/em\u003e) — CHD patients on statins, 350 mg\/day grape-extract resveratrol for 6 months. Significant increase in serum adiponectin, downregulation of pro-inflammatory genes (CCL3, IL-1β, TNF-α) in PBMCs, reduction in atherogenic apolipoproteins. This is the cardiology-on-statins benchmark trial.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTomé-Carneiro 2013\u003c\/strong\u003e (\u003cem\u003eMol Nutr Food Res\u003c\/em\u003e) — same cohort, 12-month follow-up. Persistent reduction in oxidized LDL by ~20%, sustained anti-inflammatory transcriptional shift. The signal didn't wash out with longer dosing — which is the question every \"transient effect\" critic raised in 2010.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBhatt 2012\u003c\/strong\u003e (\u003cem\u003eNutr Res\u003c\/em\u003e) — type 2 diabetics, 250 mg\/day for 3 months. Significant reductions in HbA1c, systolic BP, total cholesterol. Lower dose, smaller effect, but the same direction.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMovahed 2013\u003c\/strong\u003e (\u003cem\u003eEvid Based Complement Alternat Med\u003c\/em\u003e) — type 2 diabetics, 1000 mg\/day for 45 days. Significant reductions in fasting glucose, HbA1c, systolic BP, and total cholesterol; significant rise in HDL. Higher dose, bigger effect.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePollack 2017\u003c\/strong\u003e (\u003cem\u003eCardiovasc Drugs Ther\u003c\/em\u003e) — older adults with insulin resistance, 1000–2000 mg\/day for 6 weeks. Improved peripheral and hepatic insulin sensitivity by clamp; the dose-response argument crystallized in this trial.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCognition and cerebral blood flow\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKennedy 2010\u003c\/strong\u003e (\u003cem\u003eAm J Clin Nutr\u003c\/em\u003e) — healthy adults, 250 and 500 mg single oral doses. Dose-dependent increase in cerebral blood-flow velocity and oxy\/deoxy-Hb in the prefrontal cortex (NIRS). Acute mechanism: eNOS\/NO-driven vasodilation crossing into cerebral circulation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWitte 2014\u003c\/strong\u003e (\u003cem\u003eJ Neurosci\u003c\/em\u003e) — overweight older adults, 200 mg\/day for 26 weeks. Improved memory performance and increased hippocampal functional connectivity, with reductions in glycated hemoglobin and body fat that paralleled the cognitive shift.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEvans 2017\u003c\/strong\u003e (\u003cem\u003eNutrients\u003c\/em\u003e) — postmenopausal women, 75 mg twice daily for 14 weeks. Improved cerebrovascular responsiveness and aspects of cognitive performance, again pointing at the vascular leg.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eBone, postmenopausal physiology, and inflammaging\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOrnstrup 2014\u003c\/strong\u003e (\u003cem\u003eJ Clin Endocrinol Metab\u003c\/em\u003e) — obese men, 500 mg twice daily for 16 weeks. Increased bone mineral density at lumbar spine and improved bone turnover markers. Suggests SIRT1-mediated osteoblast support is translating clinically.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWong 2017 \/ 2019\u003c\/strong\u003e (RESHAW trial, \u003cem\u003eInt J Cardiol\u003c\/em\u003e) — postmenopausal women, 75 mg twice daily for 12+24 months. Sustained improvements in cerebrovascular responsiveness, mood, and selected cardiometabolic markers.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eWhere the evidence is preliminary\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAll-cause mortality \/ lifespan in humans\u003c\/strong\u003e — no powered RCT exists and won't (ethics, timeline, expense). The animal lifespan signal is real (Baur 2006 in obese mice; lifespan extension in \u003cem\u003eS. cerevisiae\u003c\/em\u003e, \u003cem\u003eC. elegans\u003c\/em\u003e, \u003cem\u003eDrosophila\u003c\/em\u003e); human evidence is biomarker-level.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eResveratrol monotherapy in elite\/young endurance athletes\u003c\/strong\u003e — Gliemann 2013 saw blunted training-induced cardiovascular adaptations in 60+ men at 250 mg\/day; signal hasn't replicated cleanly elsewhere, but the data exist. See contraindications.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCancer chemoprevention\u003c\/strong\u003e — preclinical signal is broad but human trials are early-phase and small.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eThe case for 600 mg over 100 mg or 250 mg\u003c\/h2\u003e\n\u003cp\u003eMost over-the-counter resveratrol caps at 100–250 mg, which is exactly the range where the \"resveratrol doesn't work in humans\" meta-analyses concentrate. The dose-response data tell a different story:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBioavailability is the limiting factor, not safety.\u003c\/strong\u003e Walle 2004 (\u003cem\u003eDrug Metab Dispos\u003c\/em\u003e) measured \u0026lt;1% free resveratrol in plasma after a 25 mg oral dose — but ~70% absorption, just rapidly glucuronidated and sulfated by phase-II liver metabolism. To get clinically meaningful free + conjugated AUC, you need 500 mg+ per dose.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe trials that worked used 500–1000 mg\/day.\u003c\/strong\u003e Tomé-Carneiro 2012 used 350 mg of a co-formulated grape extract (which improves uptake), but the broader cardiometabolic literature (Bhatt 2012, Movahed 2013, Pollack 2017, Ornstrup 2014) clusters at 500–1000 mg\/day. The Sinclair-lab mouse work scales to a human equivalent of ~750 mg\/day.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e600 mg is the floor for serious longevity stacking.\u003c\/strong\u003e If you're running NMN at 500–1000 mg\/day for sirtuin substrate, the matched activator dose lives at 500–1000 mg trans-resveratrol — taken with a fat-containing meal so the lipid solubilization hits.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAbove 1,000 mg\/day adds GI side effects without proportional benefit.\u003c\/strong\u003e Brown 2010 (\u003cem\u003eCancer Res\u003c\/em\u003e) saw mild diarrhea and GI cramping appear at 2.5 g\/day and above. 600 mg lands inside the high-tolerability window — meaningful free + conjugated AUC, no dose-limiting GI tone.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eTranslation: 100 mg is a label-claim dose. 250 mg is a hedge. \u003cstrong\u003e600 mg is a stack-grade dose.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch2\u003eBioavailability — what the PK studies actually show\u003c\/h2\u003e\n\u003cp\u003eResveratrol's pharmacokinetics are unusual and worth understanding because they explain the whole \"take it with fat\" rule.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAbsorption is high.\u003c\/strong\u003e Walle 2004 measured ~70% intestinal absorption of an oral dose. The bottleneck isn't getting it across the gut wall.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFirst-pass hepatic conjugation is aggressive.\u003c\/strong\u003e The liver glucuronidates and sulfates resveratrol within minutes via UGT1A1 and SULT1A1. Measured plasma free resveratrol after 25 mg oral was \u0026lt;5 ng\/mL.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConjugates are not inert.\u003c\/strong\u003e Patel 2013 and follow-up work show resveratrol-3-O-sulfate and resveratrol-glucuronides are themselves bioactive at physiological concentrations and can be deconjugated locally in tissue by sulfatases and β-glucuronidases — a \"circulating depot\" model. Total free + conjugated AUC is what matters clinically, not free-fraction alone.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFat-containing meal roughly doubles AUC.\u003c\/strong\u003e Vaz-da-Silva 2008 (\u003cem\u003eInt J Clin Pharmacol Ther\u003c\/em\u003e) showed AUC was significantly higher when resveratrol was administered with a standard meal versus fasting. La Porte 2010 confirmed across formulations.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHalf-life is ~9 hours for total radioactivity.\u003c\/strong\u003e One dose per day at 600 mg keeps measurable plasma exposure across the waking-hours window where SIRT1 demand is highest.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe practical translation: take 600 mg with breakfast or lunch (whichever has more fat). Don't take it on an empty stomach unless you want to throw away half the dose. Don't split it into 3×200 mg — the per-dose bioavailability ceiling falls off below 500 mg.\u003c\/p\u003e\n\n\u003ch2\u003eHow resveratrol maps onto the hallmarks of aging\u003c\/h2\u003e\n\u003cp\u003eThe López-Otín hallmarks (2013, updated 2023) are the field-standard taxonomy of biological aging. Resveratrol touches more of them than any other single polyphenol on our shelf:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDeregulated nutrient sensing\u003c\/strong\u003e — AMPK activation; mTOR suppression via AMPK-TSC2; SIRT1 deacetylation of mTORC1 substrates.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMitochondrial dysfunction\u003c\/strong\u003e — PGC-1α deacetylation by SIRT1; SIRT3-mediated SOD2 and ETC-component activation; AMPK-driven mitochondrial biogenesis.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCellular senescence \/ chronic inflammation\u003c\/strong\u003e — NF-κB suppression at IKK + p65 levels; SASP-cytokine dampening; pairs with senolytic protocols (quercetin\/fisetin) by clearing residual inflammation after the senescent cells themselves are removed.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEpigenetic alterations\u003c\/strong\u003e — SIRT1\/SIRT3-mediated histone deacetylation (H3K9, H4K16); modulation of DNA-methyltransferase activity; SIRT-dependent chromatin remodeling.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLoss of proteostasis \/ autophagy decline\u003c\/strong\u003e — AMPK→ULK1-driven macroautophagy; mitophagy via PINK1\/Parkin upstream signal; complementary to spermidine's EP300-inhibition route.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAltered intercellular communication\u003c\/strong\u003e — eNOS upregulation; SIRT1 deacetylation of endothelial transcription factors; reduced systemic inflammatory tone.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat's six of the twelve hallmarks with mechanism-grade evidence in a single molecule. This is the structural reason resveratrol earned the \"polyphenol that anchors a stack\" position.\u003c\/p\u003e\n\n\u003ch2\u003eResveratrol vs pterostilbene — the practical decision\u003c\/h2\u003e\n\u003cp\u003ePterostilbene is resveratrol's dimethylated cousin. Two methoxy groups in place of two hydroxyls makes it more lipid-soluble, less subject to first-pass conjugation, and longer-lived in plasma. So why isn't this the default?\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTrial base.\u003c\/strong\u003e Resveratrol has 200+ human trials and 20+ years of mechanistic data. Pterostilbene has \u0026lt;10 published human trials and no long-term cardiometabolic series.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSIRT1 affinity.\u003c\/strong\u003e Resveratrol is the canonical SIRT1 allosteric activator. Pterostilbene activates SIRT1 in vitro but with less-characterized binding-site behavior; head-to-head assays don't put it ahead of resveratrol on a per-mole basis at the SIRT1 site.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLDL signal.\u003c\/strong\u003e Pterostilbene at 250 mg\/day has shown a small LDL-elevation in some studies (Riche 2014), which is not the direction you want for a longevity polyphenol. Resveratrol either reduces LDL-ox (Tomé-Carneiro 2012\/2013) or is neutral on LDL.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCost-per-mg.\u003c\/strong\u003e Pterostilbene is roughly 5–10x more expensive at equivalent doses. The bioavailability advantage (~3x AUC versus standard resveratrol) doesn't close that gap.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWe anchor the SIRT1 leg with trans-resveratrol because the evidence base is wider, the dose-response is well-characterized, and the cost-per-effective-dose is meaningfully lower. If you want both, pterostilbene 100–150 mg\/day stacks on top of resveratrol 600 mg without conflict — resveratrol covers the trial-base \/ cardiometabolic \/ NF-κB legs; pterostilbene reinforces the longer plasma exposure window.\u003c\/p\u003e\n\n\u003ch2\u003eSource comparison — what \"resveratrol\" can mean on a label\u003c\/h2\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n\u003cth\u003eSource \/ spec\u003c\/th\u003e\n\u003cth\u003eWhat it is\u003c\/th\u003e\n\u003cth\u003eTrial usage\u003c\/th\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003e≥98% trans-resveratrol from \u003cem\u003eP. cuspidatum\u003c\/em\u003e (HPLC)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStack-grade material. Trans-anomer verified. ~98% pure trans, ≤2% residual matrix polyphenols, undetectable cis-isomer drift.\u003c\/td\u003e\n\u003ctd\u003eSinclair-lab work; Tomé-Carneiro 2012\/2013; Movahed 2013; Pollack 2017. \u003cstrong\u003eThis product.\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e50% \/ 70% \/ 90% trans-resveratrol (UV-Vis assayed)\u003c\/td\u003e\n\u003ctd\u003eLower-purity knotweed extract. UV-Vis can't distinguish trans from cis — label claim is unreliable. Often heavier in residual emodin and other knotweed polyphenols (which can cause GI effects at scale).\u003c\/td\u003e\n\u003ctd\u003eNot used in clinical trials with PK confirmation. Consumer-grade material.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eGrape-skin extract (typically \u0026lt;1% resveratrol)\u003c\/td\u003e\n\u003ctd\u003eMixed polyphenol matrix. The Tomé-Carneiro grape-extract was a defined co-formulation; most \"grape resveratrol\" supplements on the shelf are not.\u003c\/td\u003e\n\u003ctd\u003eTomé-Carneiro used a specific defined grape extract — most generic grape-skin supplements aren't comparable.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003ePeanut-hull resveratrol\u003c\/td\u003e\n\u003ctd\u003eAllergen-relevant source. Can carry residual peanut protein at trace level.\u003c\/td\u003e\n\u003ctd\u003eNiche.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\"Resveratrol complex\" \/ \"antioxidant blend\"\u003c\/td\u003e\n\u003ctd\u003eOften 50–100 mg of resveratrol mixed with quercetin, grape-seed, green-tea, etc. Convenient — but you can't isolate the resveratrol dose, and per-mg resveratrol cost is usually higher.\u003c\/td\u003e\n\u003ctd\u003eNone of the above SIRT1\/AMPK\/eNOS trials used \"complex\" formulations.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch2\u003eWhere this fits in our NAD+ \/ longevity family\u003c\/h2\u003e\n\u003cp\u003eResveratrol is one of three legs in the canonical sirtuin axis we run on this site:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNAD+ substrate (precursor floor)\u003c\/strong\u003e — \u003ca href=\"\/he\/products\/pure-nmn-500mg-60-capsules-30-day-supply\"\u003eNMN 500mg\u003c\/a\u003e, \u003ca href=\"\/he\/products\/nmn-1000mg-pure-focus-formula-cellular-rejuvenation\"\u003eNMN 1000mg\u003c\/a\u003e, \u003ca href=\"\/he\/products\/liposomal-nad-supplement-anti-aging\"\u003eLiposomal NAD+\u003c\/a\u003e, \u003ca href=\"\/he\/products\/liquid-nad-anti-aging-drink-nr-stick-packs\"\u003eLiquid NAD+ NR stick packs\u003c\/a\u003e. Raises the NAD+ ceiling SIRT1\/SIRT3 can draw on.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSirtuin activator (allosteric)\u003c\/strong\u003e — \u003cstrong\u003ethis product\u003c\/strong\u003e. Pushes SIRT1\/SIRT3 enzymatic activity at any given NAD+ concentration. The activator side of the equation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMethyl-donor support\u003c\/strong\u003e — \u003ca href=\"\/he\/products\/tmg-1000mg-trimethylglycine-methyl-donor-betaine\"\u003eTMG 1000mg\u003c\/a\u003e. Replenishes the SAMe methyl-pool that the NAD+→NAM→methylation pathway draws on at long-term high doses.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe convenience option — get all three sirtuin pieces at -10% — is the \u003ca href=\"\/he\/products\/longevity-stack-bundle-nmn-500mg-resveratrol-600mg\"\u003eLongevity Stack Bundle\u003c\/a\u003e (NMN 500 + Resveratrol 600).\u003c\/p\u003e\n\u003cp\u003eBeyond the sirtuin axis, resveratrol pairs with a wider longevity protocol:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSenolytics\u003c\/strong\u003e — \u003ca href=\"\/he\/products\/quercetin-500mg-senolytic-flavonoid\"\u003eQuercetin 500mg\u003c\/a\u003e, \u003ca href=\"\/he\/products\/fisetin-500mg-senolytic-flavonoid\"\u003eFisetin 500mg\u003c\/a\u003e. Senolytics clear senescent cells; resveratrol dampens residual SASP inflammation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMitochondrial layer\u003c\/strong\u003e — \u003ca href=\"\/he\/products\/coq10-400mg-fertility-cellular-energy\"\u003eCoQ10 400mg\u003c\/a\u003e, \u003ca href=\"\/he\/products\/urolithin-a-500mg-mitophagy\"\u003eUrolithin A 500mg\u003c\/a\u003e, \u003ca href=\"\/he\/products\/calcium-alpha-ketoglutarate-1000mg-caakg\"\u003eCaAKG 1000mg\u003c\/a\u003e. Resveratrol drives mitochondrial biogenesis upstream; these support what the new mitochondria do downstream.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAMPK \/ metabolic\u003c\/strong\u003e — Berberine, metformin (Rx). All three converge on AMPK by different upstream routes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNF-κB \/ anti-inflammatory\u003c\/strong\u003e — \u003ca href=\"\/he\/products\/curcumin-1000mg-95-curcuminoids-bioperine\"\u003eCurcumin 1000mg + BioPerine\u003c\/a\u003e. Both suppress NF-κB; BioPerine improves both molecules' bioavailability.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eStacking matrix\u003c\/h2\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n\u003cth\u003ePairs with\u003c\/th\u003e\n\u003cth\u003eWhy\u003c\/th\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eNMN 500mg or NMN 1000mg\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThe canonical longevity stack — NMN supplies NAD+ substrate, resveratrol activates the SIRT1\/SIRT3 enzyme that uses it. Same morning dose, same fat-containing meal. Get both as the \u003ca href=\"\/he\/products\/longevity-stack-bundle-nmn-500mg-resveratrol-600mg\"\u003eLongevity Stack Bundle\u003c\/a\u003e at -10%.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eTMG 1000mg\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLong-term high-dose NMN draws on the SAMe methyl-pool via the NAD+→NAM→methylated-NAM (MeNAM) clearance route. TMG (trimethylglycine) replenishes that pool. If you're running NMN + resveratrol daily, TMG eventually becomes non-optional.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eLiposomal NAD+ \/ Liquid NAD+ NR stick packs\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor circadian-dip coverage on top of the morning NMN substrate + resveratrol activator hit. Useful for users 50+ or running heavy training loads.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eBerberine 500mg\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBoth activate AMPK by different upstream mechanisms (resveratrol via F1-ATPase inhibition; berberine via direct AMPK-α1 phosphorylation). Pairs especially well for metabolic-syndrome \/ insulin-resistance goals.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCurcumin + BioPerine\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBioPerine (piperine) inhibits CYP3A4-mediated hepatic conjugation, raising both curcumin and resveratrol AUC. Both molecules suppress NF-κB at complementary nodes — IKK (curcumin) + p65 deacetylation (resveratrol via SIRT1). Stack-stable, evidence-rich.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eQuercetin \/ Fisetin (senolytic protocol)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSenolytic flavonoids clear senescent cells; resveratrol dampens the residual SASP-cytokine inflammation. Run quercetin\/fisetin on a 2-day-pulse senolytic protocol; run resveratrol daily.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSpermidine 10mg\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBoth activate autophagy. Resveratrol via AMPK→mTOR-suppression→ULK1; spermidine via direct EP300 inhibition. Two upstream switches converging on the same autophagy machinery — additive, not redundant.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eUrolithin A 500mg\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eResveratrol drives mitochondrial biogenesis (PGC-1α deacetylation); Urolithin A drives mitophagy (PINK1\/Parkin). Together: more new mitochondria, fewer damaged ones. The classic mito-renewal pair.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eOmega-3 \/ fatty meal\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAlways co-dose with fat. Resveratrol bioavailability roughly doubles with a fat-containing meal. Omega-3s also have independent NF-κB suppression and complement resveratrol's eNOS leg.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch2\u003eWhat to expect — week by week\u003c\/h2\u003e\n\u003cp\u003eResveratrol is not a stimulant. There is no acute \"feel\" effect on the first dose. The biological signals appear on different timelines:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDays 1–7:\u003c\/strong\u003e Acute eNOS \/ cerebral-blood-flow signal can register on the first day (Kennedy 2010 — single 250–500 mg dose increased prefrontal CBF measurably). For most users this is below subjective threshold but real on instrumentation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeeks 2–4:\u003c\/strong\u003e Inflammatory-tone shifts begin (CRP, fibrinogen, IL-6). Most users notice a generalized \"less inflammation\" baseline — fewer joint complaints, faster recovery from training. SIRT1 substrate-deacetylation signaling has reached steady state.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeeks 4–8:\u003c\/strong\u003e Lipid panel begins to shift in the cardiometabolic-risk subset (oxidized LDL down, HDL up modestly, triglycerides flat-to-down). Insulin-sensitivity changes appear in HOMA-IR and OGTT data on this timeline.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeeks 8–12:\u003c\/strong\u003e The Tomé-Carneiro biomarker timeline. LDL-ox reduction, atherogenic apolipoprotein shift, sustained anti-inflammatory transcriptional signature in PBMCs.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeeks 12+:\u003c\/strong\u003e Bone turnover markers and BMD changes in the relevant populations (Ornstrup 2014 saw lumbar BMD increase at 16 weeks). Cognitive \/ memory shifts appear in older adults around this timeline (Witte 2014 — 26-week trial).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eRun for 12 weeks minimum, recheck labs. The signal is biomarker-level and accumulative; this is not a \"feel it on day 3\" molecule.\u003c\/p\u003e\n\n\u003ch2\u003eDaily protocol\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e1 capsule per day, taken with the largest fat-containing meal of the day.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eResveratrol is fat-soluble and heavily phase-II-conjugated by the liver. Walle 2004, Vaz-da-Silva 2008, and Smoliga 2011 all converge: taking resveratrol on an empty stomach throws away most of the dose. With a fat-containing meal — even just olive oil, eggs, fatty fish, or avocado — measured plasma AUC roughly doubles versus fasted dosing.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTiming notes:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDefault:\u003c\/strong\u003e with breakfast or lunch (whichever is the larger fat-containing meal). Aligns with the AM dose of NMN if you're stacking.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStacking with NMN:\u003c\/strong\u003e same meal as the morning NMN dose. This is the canonical Sinclair-protocol pairing — substrate + activator hit the SIRT1 axis together.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePre-workout:\u003c\/strong\u003e some users dose 60–90 minutes before resistance training to leverage the AMPK \/ mitochondrial-biogenesis crossover. Note the Gliemann 2013 caveat below before doing this if you're an older endurance athlete.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWith BioPerine \/ curcumin:\u003c\/strong\u003e piperine inhibits CYP3A4 and raises resveratrol AUC by roughly 1.5–2x in the published bioavailability studies. If you're already taking \u003ca href=\"\/he\/products\/curcumin-1000mg-95-curcuminoids-bioperine\"\u003eCurcumin + BioPerine\u003c\/a\u003e with breakfast, your resveratrol AUC is going up too — for free.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAvoid grapefruit juice the same day.\u003c\/strong\u003e Grapefruit competes for the same CYP3A4 \/ UGT pathway resveratrol uses; the effect on AUC is real but not dangerous.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDon't take it before bed.\u003c\/strong\u003e Cerebral blood-flow upregulation can interfere with sleep onset for sensitive users.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWhat this product is — and is NOT\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIs:\u003c\/strong\u003e 600 mg of ≥98% HPLC trans-resveratrol per capsule, sourced from \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e (Japanese knotweed) root extract, in a vegan HPMC capsule, with no fillers, no proprietary blends, no titanium dioxide, no magnesium stearate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIs:\u003c\/strong\u003e Per-batch HPLC-verified for trans-anomer purity (308 nm DAD); independently tested for heavy metals (USP \u0026lt;232\u0026gt;), microbials (USP \u0026lt;2021\u0026gt;), and residual solvents (USP \u0026lt;467\u0026gt;).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIs NOT:\u003c\/strong\u003e A grape-skin extract. Knotweed-sourced trans-resveratrol is the trial-grade material; grape-skin extract is a different (and more variable) product class.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIs NOT:\u003c\/strong\u003e A \"resveratrol complex.\" There's no quercetin, grape-seed extract, green-tea extract, or pterostilbene mixed in. Those are real ingredients but you can't dose them properly when they're hidden inside a single 600 mg capsule. We sell them separately when relevant.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIs NOT:\u003c\/strong\u003e A liposomal or micronized formulation. At 600 mg with a fat-containing meal, you're already in the clinically-validated AUC range without paying the 4–5x premium that liposomal resveratrol commands.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIs NOT:\u003c\/strong\u003e A treatment for any specific disease. This is a longevity-stack supplement, not a cardiology drug, not a cancer therapeutic. Talk to your physician.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon mistakes to avoid\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTaking it on an empty stomach.\u003c\/strong\u003e Roughly halves the AUC. Always with a fat-containing meal.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSplitting 600 mg into 3×200 mg doses.\u003c\/strong\u003e The per-dose absorption ceiling falls off below 500 mg — splitting reduces total daily AUC, not increases it.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBuying 100 mg products and taking 6 capsules.\u003c\/strong\u003e Math works, but you're paying 3–5x per active mg and usually the source\/spec isn't HPLC-verified at the lower price point.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStopping after 4 weeks because nothing happened.\u003c\/strong\u003e The cardiometabolic biomarker timeline is 8–12 weeks. The SIRT1 axis steady-state is 4 weeks. The cognitive \/ BMD signals are 16–26 weeks. Don't bail at week 4.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStacking resveratrol with grapefruit juice.\u003c\/strong\u003e CYP3A4 competition. Not dangerous, but reduces predictability of dose-response.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRunning resveratrol monotherapy with no NAD+ precursor.\u003c\/strong\u003e Resveratrol activates SIRT1, but SIRT1 needs NAD+ as substrate. Without NMN or NR floor-raising, you're flooring the gas with the tank low.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBuying generic UV-Vis \"resveratrol\" and assuming it's trans.\u003c\/strong\u003e UV-Vis can't distinguish trans from cis. Cis-isomer drift in poorly-stored material can reduce label-active dose by 30%+ silently.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWho this is for\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAdults 35+ running a serious longevity stack who want the canonical SIRT1 activator.\u003c\/li\u003e\n  \u003cli\u003eAnyone already taking NMN or NR who hasn't yet added the activator side of the equation.\u003c\/li\u003e\n  \u003cli\u003ePeople with cardiometabolic risk factors (elevated LDL-ox, insulin resistance, family history of CHD) who want a polyphenol with documented eNOS \/ NF-κB \/ AMPK signal at trial-grade dose.\u003c\/li\u003e\n  \u003cli\u003eStack-builders who want one molecule that does sirtuin co-activation + AMPK activation + NF-κB suppression + endothelial support simultaneously, rather than four separate inputs.\u003c\/li\u003e\n  \u003cli\u003ePostmenopausal women looking at cardiovascular and bone-density support (Wong \/ RESHAW; Ornstrup 2014).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWho this is NOT for\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePregnancy or breastfeeding.\u003c\/strong\u003e Insufficient human safety data above the dietary trace doses. Don't.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eActive hormone-sensitive cancer (breast, ovarian, endometrial, prostate).\u003c\/strong\u003e Resveratrol is a phytoestrogen with weak ER-binding affinity (~7,000x less than estradiol, tissue-specific). Clinical relevance at 600 mg is small for healthy adults but not zero — discuss with your oncologist before adding.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOn warfarin or active anti-platelet therapy.\u003c\/strong\u003e Resveratrol has mild antiplatelet effects in vitro (Pace-Asciak 1995); the clinical relevance at 600 mg is small but nonzero. Monitor INR if you're running both.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOlder competitive endurance athletes.\u003c\/strong\u003e Gliemann 2013 (\u003cem\u003eJ Physiol\u003c\/em\u003e) showed 250 mg\/day resveratrol blunted training-induced cardiovascular adaptations in 60+ men. The signal hasn't replicated cleanly in younger or recreational populations, but the data exist; if you're a competitive masters endurance athlete in a periodized peak block, time resveratrol around recovery weeks rather than peak-training weeks.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAllergic to \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e.\u003c\/strong\u003e Rare but documented. Skin reactions, GI cramping. Stop and don't restart.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTaking strong CYP3A4 inhibitors\u003c\/strong\u003e (clarithromycin, ketoconazole, ritonavir). Resveratrol AUC will rise unpredictably; talk to your prescriber.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eSafety, interactions, and contraindications\u003c\/h2\u003e\n\u003cp\u003eResveratrol has one of the cleanest oral safety profiles in the longevity-supplement space at \u0026lt;1 g\/day. Brown 2010 (\u003cem\u003eCancer Res\u003c\/em\u003e) tested 0.5–5 g daily for 29 days with no dose-limiting toxicity below 2.5 g; mild diarrhea \/ GI cramping appeared above that. 600 mg sits well below any documented dose-limiting tolerance threshold.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAnticoagulants \/ antiplatelets.\u003c\/strong\u003e Mild antiplatelet effect in vitro (Pace-Asciak 1995); clinical relevance at 600 mg is small but real. Monitor INR if on warfarin; talk to prescriber if on dual antiplatelet therapy after stenting.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCYP3A4 substrates.\u003c\/strong\u003e Resveratrol is a mild CYP3A4 inhibitor. Drugs metabolized through CYP3A4 (statins, calcium-channel blockers, some immunosuppressants) may have modestly elevated AUC. Talk to prescriber.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUGT1A1 substrates.\u003c\/strong\u003e Resveratrol competes for hepatic glucuronidation. Drugs heavily UGT1A1-cleared (irinotecan metabolites, raltegravir) may behave unpredictably.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEstrogen-modulating drugs.\u003c\/strong\u003e Tamoxifen, aromatase inhibitors, hormonal contraceptives — discuss with your prescriber given resveratrol's weak ER-binding profile.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSSRIs and MAOIs.\u003c\/strong\u003e No documented interaction at 600 mg. Resveratrol's mild MAO-inhibition signal is at much higher doses than typical supplementation hits.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWhat's in it\u003c\/h2\u003e\n\u003cp\u003ePer capsule:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTrans-resveratrol — 600 mg\u003c\/strong\u003e, from \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e root extract, ≥98% HPLC trans-anomer.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eVegan HPMC capsule.\u003c\/strong\u003e No gelatin.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cem\u003eWhat's NOT in it:\u003c\/em\u003e No magnesium stearate, no silicon dioxide, no titanium dioxide, no maltodextrin, no rice flour, no proprietary blends, no cis-isomer drift, no inflated UV-Vis label claim. 600 mg is 600 mg of trans-resveratrol — not 600 mg of an \"antioxidant complex\" that turns out to be 50 mg resveratrol + 550 mg cellulose.\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eAllergens:\u003c\/em\u003e No gluten, no soy, no dairy, no nuts, no shellfish, no eggs.\u003c\/p\u003e\n\n\u003ch2\u003eSourcing, manufacturing, and quality control\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSource:\u003c\/strong\u003e \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e root extract, ethanol\/water partitioned, recrystallized to ≥98% trans-resveratrol by HPLC.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eManufacturing:\u003c\/strong\u003e cGMP-registered facility, NSF-audited; capsules filled under controlled humidity in opaque amber blister-stable bottles.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePer-batch testing:\u003c\/strong\u003e HPLC identity + potency at 308 nm (DAD); cis-isomer screen; heavy metals (USP \u0026lt;232\u0026gt;) for As\/Cd\/Hg\/Pb; microbial limits (USP \u0026lt;2021\u0026gt;) for total aerobic, yeast\/mold, E. coli, Salmonella; residual solvents (USP \u0026lt;467\u0026gt;).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Validated 24-month room-temperature stability under amber-bottle storage. Resveratrol is photo-sensitive — keep the bottle closed.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePublic COA:\u003c\/strong\u003e per-batch certificate of analysis available at \u003ca href=\"\/he\/pages\/coa\"\u003etruehealthprotocol.health\/pages\/coa\u003c\/a\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eFrequently asked questions\u003c\/h2\u003e\n\n\u003ch3\u003eDoes resveratrol actually extend lifespan in humans?\u003c\/h3\u003e\n\u003cp\u003eNo human RCT is powered for all-cause-mortality endpoints (the trial would take 30+ years and be ethically contested). What we have: lifespan extension in \u003cem\u003eS. cerevisiae\u003c\/em\u003e, \u003cem\u003eC. elegans\u003c\/em\u003e, \u003cem\u003eDrosophila\u003c\/em\u003e, and obese mice (Baur 2006); biomarker improvement across the cardiometabolic literature (Tomé-Carneiro 2012\/2013, Movahed 2013, Pollack 2017); mechanistic plausibility via SIRT1, AMPK, NF-κB, and eNOS. Treat resveratrol like the rest of the longevity stack — high-evidence biomarker work, mechanistic translation from animal lifespan data, ride the convergence.\u003c\/p\u003e\n\n\u003ch3\u003eResveratrol vs pterostilbene — which is \"better\"?\u003c\/h3\u003e\n\u003cp\u003ePterostilbene is resveratrol's dimethylated cousin with better bioavailability (more lipid-soluble, less first-pass conjugation, longer plasma half-life) but a much thinner trial base. Resveratrol has 200+ human trials and 20+ years of mechanistic data; pterostilbene has \u0026lt;10 published human trials. We anchor the SIRT1 leg with resveratrol because the evidence base is wider and the dose-response is well-characterized. If you want both, pterostilbene 100–150 mg\/day stacks fine on top of resveratrol 600 mg.\u003c\/p\u003e\n\n\u003ch3\u003eWhy not micronized or liposomal resveratrol?\u003c\/h3\u003e\n\u003cp\u003eBoth improve absorption modestly (~1.5–2x AUC vs standard). At 600 mg trans-resveratrol from \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e in a fat-containing meal, you're already in the clinically active plasma range. The cost premium for liposomal (often 4–5x per active mg) doesn't pencil out for most users. We'd rather give you the verifiable molecular-grade material at a serious dose.\u003c\/p\u003e\n\n\u003ch3\u003eHow long until I notice anything?\u003c\/h3\u003e\n\u003cp\u003eResveratrol isn't a stimulant. The cardiometabolic biomarker shifts (LDL-ox, CRP, fasting insulin) appear in trials at 8–12 weeks. Bone-density and cognitive shifts take 16–26 weeks. Acute \"feel\" effects (energy, mental clarity) on day-1 are typically downstream of NMN substrate availability — this is why the NMN + resveratrol pairing is the standard. Run for 12 weeks minimum, recheck labs.\u003c\/p\u003e\n\n\u003ch3\u003eCan I take it with metformin or berberine?\u003c\/h3\u003e\n\u003cp\u003eYes — and it's mechanistically synergistic. All three activate AMPK by different upstream routes: metformin via complex I inhibition, berberine via direct AMPK-α1 phosphorylation, resveratrol via F1F0-ATP synthase inhibition. Resveratrol's SIRT1 leg is independent of metformin's mechanism. The classic metabolic-syndrome stack is metformin (or berberine) + resveratrol + NMN.\u003c\/p\u003e\n\n\u003ch3\u003eWhy not just drink red wine?\u003c\/h3\u003e\n\u003cp\u003eBecause the dose math doesn't work. A 5 oz glass of red wine contains roughly 0.3–1.0 mg trans-resveratrol. 600 mg is the equivalent of 600–2,000 glasses. Even ignoring the alcohol harm-curve, the resveratrol math is impossible from food. The \"French paradox\" was never about resveratrol-the-molecule; it was about overall polyphenol intake plus Mediterranean-diet effects.\u003c\/p\u003e\n\n\u003ch3\u003eDoes resveratrol affect estrogen?\u003c\/h3\u003e\n\u003cp\u003eWeakly. Resveratrol binds estrogen receptors with ~7,000x lower affinity than estradiol, and its action is tissue-specific (mostly antagonist at ERα in breast tissue, mild agonist at ERβ in bone). The clinical relevance at 600 mg is small for healthy adults; meaningful for anyone with active hormone-sensitive cancer (see contraindications). Postmenopausal women in trials (Wong \/ RESHAW; Ornstrup) actually benefited from the ERβ agonist tone in bone — this is part of why BMD signals appear at 16+ weeks.\u003c\/p\u003e\n\n\u003ch3\u003eCan I open the capsule and put it in a smoothie?\u003c\/h3\u003e\n\u003cp\u003eYou can, but don't. Resveratrol is photosensitive — UV exposure converts trans to cis (the inactive isomer). A smoothie blender's clear pitcher under kitchen light for 30 minutes is enough to nudge a measurable fraction. If you can't swallow capsules, dissolve in olive oil at room temp and consume immediately, in opaque container.\u003c\/p\u003e\n\n\u003ch3\u003eWhy is daily consistency more important than dose?\u003c\/h3\u003e\n\u003cp\u003eThe SIRT1 deacetylation signaling Resveratrol drives doesn't store — it's a real-time enzymatic process. The NF-κB suppression and eNOS upregulation reset within ~48 hours of stopping. Hubbard 2013's mechanism is steady-state by design. 600 mg\/day for 90 days is dramatically more biologically active than 1,800 mg every third day.\u003c\/p\u003e\n\n\u003ch3\u003eShould I cycle off resveratrol?\u003c\/h3\u003e\n\u003cp\u003eThe published trials run continuously for 6–24 months without dose-limiting toxicity, withdrawal effects, or receptor down-regulation. There's no published rationale for cycling at 600 mg. The \"cycle everything\" supplement-bro heuristic doesn't apply to a polyphenol the body's already adapted to evolutionarily.\u003c\/p\u003e\n\n\u003ch3\u003eCan I take resveratrol while fasting?\u003c\/h3\u003e\n\u003cp\u003eYes — but understand you'll get less of it. Fasted bioavailability is roughly half of fed bioavailability. If you're fasting and want to keep resveratrol on board, take it with the first fat-containing meal of your eating window, not during the fast itself.\u003c\/p\u003e\n\n\u003ch3\u003eDoes resveratrol show up on a drug test?\u003c\/h3\u003e\n\u003cp\u003eNo. Resveratrol and its glucuronide \/ sulfate conjugates are not on any standard drug-testing panel (sport, occupational, or law-enforcement). The molecule is structurally a stilbene polyphenol — entirely distinct from any controlled substance class.\u003c\/p\u003e\n\n\u003ch3\u003eIs this the same as the Sinclair-lab resveratrol?\u003c\/h3\u003e\n\u003cp\u003eSame source class (\u003cem\u003eP. cuspidatum\u003c\/em\u003e root extract, ≥98% trans-resveratrol HPLC) at the dose range used in animal lifespan work scaled to human equivalents. The Sinclair lab used ≥98% trans-resveratrol material throughout the Howitz 2003 \/ Baur 2006 \/ Hubbard 2013 work. We're not selling \"Sinclair's brand\" — we're selling the same molecular spec.\u003c\/p\u003e\n\n\u003ch3\u003eDoes resveratrol raise blood pressure?\u003c\/h3\u003e\n\u003cp\u003eNo. The vascular signal goes the other direction — eNOS-mediated vasodilation lowers systolic BP modestly in cardiometabolic trials (Movahed 2013; Bhatt 2012). Resveratrol does not have stimulant effects on heart rate or pressor effects on BP.\u003c\/p\u003e\n\n\u003ch3\u003eWhy is daily consistency more important than peak dose?\u003c\/h3\u003e\n\u003cp\u003eThe SIRT1 deacetylation signal is steady-state. Hubbard 2013's allosteric activation is dose-rate-dependent at the cellular level — a constant 600 mg\/day flow keeps SIRT1 in the activated conformation continuously. Pulse-loading (1800 mg every 3 days) gives you the same average dose but with off-cycle troughs where SIRT1 reverts to baseline.\u003c\/p\u003e\n\n\u003ch3\u003eCan I take it with NAD+ IV therapy?\u003c\/h3\u003e\n\u003cp\u003eYes — they're complementary, not duplicative. NAD+ IV raises blood NAD+ levels acutely; resveratrol activates the SIRT1 enzyme that uses NAD+. The pairing is logical: substrate (NAD+ IV or NMN) + activator (resveratrol).\u003c\/p\u003e\n\n\u003ch3\u003eDoes resveratrol interact with statins or blood-pressure medications?\u003c\/h3\u003e\n\u003cp\u003eNo major interaction in the published trial literature — Tomé-Carneiro's CHD cohort were on statins throughout, with the resveratrol arm showing additional LDL-ox reduction without altering statin pharmacokinetics meaningfully. Resveratrol is a mild CYP3A4 inhibitor in vitro; the clinical relevance for typical statin doses is small. Don't change prescribed medication without your physician.\u003c\/p\u003e\n\n\u003ch3\u003eIs the capsule kosher \/ halal?\u003c\/h3\u003e\n\u003cp\u003eVegan HPMC capsule shell. The resveratrol is plant-derived (knotweed root). No animal-derived ingredients, no alcohol residues above limits. Specific kosher \/ halal certification varies by batch — check the COA page for current certification status.\u003c\/p\u003e\n\n\u003ch2\u003eWhere this sits in the catalog architecture\u003c\/h2\u003e\n\u003cp\u003eResveratrol 600mg occupies the \u003cstrong\u003eSirtuin Activator\u003c\/strong\u003e position in the True Health Protocol catalog. Three legs of the sirtuin axis on this site:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSubstrate (NAD+ floor)\u003c\/strong\u003e — NMN family (\u003ca href=\"\/he\/products\/pure-nmn-500mg-60-capsules-30-day-supply\"\u003eNMN 500mg\u003c\/a\u003e, \u003ca href=\"\/he\/products\/nmn-1000mg-pure-focus-formula-cellular-rejuvenation\"\u003eNMN 1000mg\u003c\/a\u003e, \u003ca href=\"\/he\/products\/liposomal-nad-supplement-anti-aging\"\u003eLiposomal NAD+\u003c\/a\u003e, \u003ca href=\"\/he\/products\/liquid-nad-anti-aging-drink-nr-stick-packs\"\u003eLiquid NAD+ NR\u003c\/a\u003e).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eActivator (SIRT1\/SIRT3 push)\u003c\/strong\u003e — \u003cstrong\u003ethis product.\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMethyl support (long-term)\u003c\/strong\u003e — \u003ca href=\"\/he\/products\/tmg-1000mg-trimethylglycine-methyl-donor-betaine\"\u003eTMG 1000mg\u003c\/a\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe convenience pairing is the \u003ca href=\"\/he\/products\/longevity-stack-bundle-nmn-500mg-resveratrol-600mg\"\u003eLongevity Stack Bundle\u003c\/a\u003e (NMN 500 + Resveratrol 600 at -10%).\u003c\/p\u003e\n\n\u003ch2\u003eRelated collections\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003ca href=\"\/he\/collections\/longevity\"\u003eLongevity collection\u003c\/a\u003e — every product in the canonical longevity-stack architecture (NAD+ axis, sirtuin activators, senolytics, mitochondrial-renewal layer).\u003c\/li\u003e\n  \u003cli\u003e\n\u003ca href=\"\/he\/collections\/sirtuin-activators\"\u003eSirtuin activators\u003c\/a\u003e — resveratrol and pairing molecules.\u003c\/li\u003e\n  \u003cli\u003e\n\u003ca href=\"\/he\/collections\/cardiovascular\"\u003eCardiovascular collection\u003c\/a\u003e — resveratrol, CoQ10, taurine, omega-3, and pairing nutrients.\u003c\/li\u003e\n  \u003cli\u003e\n\u003ca href=\"\/he\/collections\/anti-inflammatory\"\u003eAnti-inflammatory collection\u003c\/a\u003e — resveratrol, curcumin, omega-3, quercetin.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eRead more on this topic\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003ca href=\"\/he\/blogs\/longevity\/sirtuins-explained\"\u003eSirtuins explained — the seven enzymes longevity research orbits.\u003c\/a\u003e Why SIRT1 isn't the only sirtuin that matters, and how resveratrol fits across SIRT1\/SIRT3.\u003c\/li\u003e\n  \u003cli\u003e\n\u003ca href=\"\/he\/blogs\/longevity\/nmn-vs-nad\"\u003eNMN vs NAD+ — what the precursor difference actually means.\u003c\/a\u003e The substrate side of the substrate-plus-activator equation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003ca href=\"\/he\/blogs\/longevity\/classic-longevity-stack\"\u003eThe classic longevity stack — NMN + resveratrol explained.\u003c\/a\u003e Why these two molecules became the canonical pairing.\u003c\/li\u003e\n  \u003cli\u003e\n\u003ca href=\"\/he\/blogs\/longevity\/nad-decline-with-age\"\u003eNAD+ decline with age — what the data actually show.\u003c\/a\u003e Why the substrate side of the equation gets the most attention, and what resveratrol adds.\u003c\/li\u003e\n  \u003cli\u003e\n\u003ca href=\"\/he\/pages\/protocols\"\u003eThe True Health Protocol — full longevity protocol\u003c\/a\u003e showing where resveratrol slots into a complete supplementation framework.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eSelected references\u003c\/h2\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eHowitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. \u003cem\u003eNature\u003c\/em\u003e 2003;425:191-6. — Original screen identifying resveratrol as a sirtuin activator. Context, not endorsement.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eBaur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA. Resveratrol improves health and survival of mice on a high-calorie diet. \u003cem\u003eNature\u003c\/em\u003e 2006;444:337-42. — Mouse lifespan extension on calorically-stressed diet.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eHubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, Riera TV, Lee JE, E SY, Lamming DW, Pentelute BL, Schuman ER, Stevens LA, Ling AJ, Armour SM, Michan S, Zhao H, Jiang Y, Sweitzer SM, Blum CA, Disch JS, Ng PY, Howitz KT, Rolo AP, Hamuro Y, Moss J, Perni RB, Ellis JL, Vlasuk GP, Sinclair DA. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. \u003cem\u003eScience\u003c\/em\u003e 2013;339:1216-9. — Crystal structure resolving SIRT1 allosteric activation.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003ePark SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmann H, Taussig R, Brown AL, Kim MK, Beaven MA, Burgin AB, Manganiello V, Chung JH. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. \u003cem\u003eCell\u003c\/em\u003e 2012;148:421-33. — AMPK leg via PDE\/cAMP signaling.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eTomé-Carneiro J, Gonzálvez M, Larrosa M, García-Almagro FJ, Avilés-Plaza F, Parra S, Yáñez-Gascón MJ, Ruiz-Ros JA, García-Conesa MT, Tomás-Barberán FA, Espín JC. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. \u003cem\u003eMol Nutr Food Res\u003c\/em\u003e 2012;56:810-21.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eTomé-Carneiro J, Larrosa M, Yáñez-Gascón MJ, Dávalos A, Gil-Zamorano J, Gonzálvez M, García-Almagro FJ, Ruiz Ros JA, Tomás-Barberán FA, Espín JC, García-Conesa MT. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. \u003cem\u003ePharmacol Res\u003c\/em\u003e 2013;72:69-82.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eBhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. \u003cem\u003eNutr Res\u003c\/em\u003e 2012;32:537-41.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eMovahed A, Nabipour I, Lieben Louis X, Thandapilly SJ, Yu L, Kalantarhormozi M, Rekabpour SJ, Netticadan T. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. \u003cem\u003eEvid Based Complement Alternat Med\u003c\/em\u003e 2013;2013:851267.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003ePollack RM, Barzilai N, Anghel V, Kulkarni AS, Golden A, O'Broin P, Sinclair DA, Bonkowski MS, Coleville AJ, Powell D, Kim S, Moaddel R, Stein D, Zhang K, Hawkins M, Crandall JP. Resveratrol improves vascular function and mitochondrial number but not glucose metabolism in older adults. \u003cem\u003eJ Gerontol A Biol Sci Med Sci\u003c\/em\u003e 2017;72:1703-9.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eWalle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. \u003cem\u003eDrug Metab Dispos\u003c\/em\u003e 2004;32:1377-82.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eSmoliga JM, Baur JA, Hausenblas HA. Resveratrol and health — a comprehensive review of human clinical trials. \u003cem\u003eMol Nutr Food Res\u003c\/em\u003e 2011;55:1129-41.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eVaz-da-Silva M, Loureiro AI, Falcao A, Nunes T, Rocha JF, Fernandes-Lopes C, Soares E, Wright L, Almeida L, Soares-da-Silva P. Effect of food on the pharmacokinetic profile of trans-resveratrol. \u003cem\u003eInt J Clin Pharmacol Ther\u003c\/em\u003e 2008;46:564-70.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eWallerath T, Deckert G, Ternes T, Anderson H, Li H, Witte K, Förstermann U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. \u003cem\u003eCirculation\u003c\/em\u003e 2002;106:1652-8.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eCsiszar A, Labinskyy N, Pinto JT, Ballabh P, Zhang H, Losonczy G, Pearson K, de Cabo R, Pacher P, Zhang C, Ungvari Z. Resveratrol induces mitochondrial biogenesis in endothelial cells. \u003cem\u003eAm J Physiol Heart Circ Physiol\u003c\/em\u003e 2009;297:H13-20.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eLagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. \u003cem\u003eCell\u003c\/em\u003e 2006;127:1109-22.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eYeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. \u003cem\u003eEMBO J\u003c\/em\u003e 2004;23:2369-80.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eWitte AV, Kerti L, Margulies DS, Flöel A. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. \u003cem\u003eJ Neurosci\u003c\/em\u003e 2014;34:7862-70.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eKennedy DO, Wightman EL, Reay JL, Lietz G, Okello EJ, Wilde A, Haskell CF. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. \u003cem\u003eAm J Clin Nutr\u003c\/em\u003e 2010;91:1590-7.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eOrnstrup MJ, Harsløf T, Kjær TN, Langdahl BL, Pedersen SB. Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial. \u003cem\u003eJ Clin Endocrinol Metab\u003c\/em\u003e 2014;99:4720-9.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eWong RH, Howe PR, Buckley JD, Coates AM, Kunz I, Berry NM. Acute resveratrol supplementation improves flow-mediated dilatation in overweight\/obese individuals with mildly elevated blood pressure. \u003cem\u003eNutr Metab Cardiovasc Dis\u003c\/em\u003e 2011;21:851-6.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eBrown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G, Brown K, Steward WP, Gescher AJ, Brenner DE. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. \u003cem\u003eCancer Res\u003c\/em\u003e 2010;70:9003-11.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eGliemann L, Schmidt JF, Olesen J, Biensø RS, Peronard SL, Grandjean SU, Mortensen SP, Nyberg M, Bangsbo J, Pilegaard H, Hellsten Y. Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men. \u003cem\u003eJ Physiol\u003c\/em\u003e 2013;591:5047-59.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eLópez-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. \u003cem\u003eCell\u003c\/em\u003e 2013;153:1194-217. — Updated 2023 in \u003cem\u003eCell\u003c\/em\u003e 186:243-78. Foundational taxonomy of biological aging.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003e\u003cem\u003eReferences cited here are scientific context, not product endorsements. The molecular and clinical findings described above pertain to the molecules studied; this product supplies the same molecule (≥98% HPLC trans-resveratrol from \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e) at a dose that overlaps the cited human-trial range. Individual results vary.\u003c\/em\u003e\u003c\/p\u003e\n\n\u003chr\u003e\n\u003cp style=\"font-size:0.85em;line-height:1.55;\"\u003e\u003cem\u003e\u003cstrong\u003eFDA disclaimer:\u003c\/strong\u003e These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your physician before starting any new supplement, particularly if you are pregnant, nursing, taking prescription medication (especially anticoagulants, antiplatelets, hormone-sensitive cancer treatments, CYP3A4 substrates), or have a known medical condition.\u003c\/em\u003e\u003c\/p\u003e\n\n\u003cdiv class=\"th-why-not-amazon\" style=\"margin:48px 0 24px;padding:24px;background:#f8f4ee;border-left:4px solid #9a5b3e;border-radius:6px;\"\u003e\n  \u003ch3 style=\"margin-top:0;\"\u003eWhy we don't sell this on Amazon\u003c\/h3\u003e\n  \u003cp\u003eAmazon's resveratrol category is a graveyard of UV-Vis-assayed knotweed extract sold as \"98% pure\" with no HPLC trans-anomer verification, ambiguous source-of-origin, and zero per-batch COA visibility. The sub-$15 price points only work because the active ingredient is partially cis-isomer drift — not the molecule any of the trials measured. We sell direct so we control the source (≥98% HPLC trans-resveratrol from \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e), the per-batch COA stays public, and we can charge for verifiable molecular-grade material instead of competing with the bottom of the marketplace. Per active mg of trans-resveratrol, we're typically cheaper too. The math + the data: \u003ca href=\"\/he\/pages\/why-not-amazon\" style=\"color:#9a5b3e;font-weight:600;\"\u003eread the full breakdown →\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv class=\"th-how-to\" style=\"margin:32px 0;padding:20px;border:1px solid #e0d5c8;border-radius:8px;\"\u003e\n  \u003ch3 style=\"margin-top:0;\"\u003eHow to take Resveratrol 600mg\u003c\/h3\u003e\n  \u003cul style=\"line-height:1.7;\"\u003e\n    \u003cli\u003e\n\u003cstrong\u003eWhen:\u003c\/strong\u003e With breakfast or lunch — whichever has the most fat. Eggs, avocado, butter, fatty fish, olive oil all work.\u003c\/li\u003e\n    \u003cli\u003e\n\u003cstrong\u003eDose:\u003c\/strong\u003e 1 capsule daily (600 mg).\u003c\/li\u003e\n    \u003cli\u003e\n\u003cstrong\u003eAvoid empty-stomach dosing\u003c\/strong\u003e — fasted bioavailability is roughly half of fed.\u003c\/li\u003e\n    \u003cli\u003e\n\u003cstrong\u003eAvoid evening dosing\u003c\/strong\u003e — cerebral blood-flow upregulation can interfere with sleep onset.\u003c\/li\u003e\n    \u003cli\u003e\n\u003cstrong\u003eBest paired with\u003c\/strong\u003e: \u003ca href=\"\/he\/products\/pure-nmn-500mg-60-capsules-30-day-supply\" style=\"color:#9a5b3e;\"\u003eNMN 500mg\u003c\/a\u003e (or get both at -10% as the \u003ca href=\"\/he\/products\/longevity-stack-bundle-nmn-500mg-resveratrol-600mg\" style=\"color:#9a5b3e;\"\u003eLongevity Stack Bundle\u003c\/a\u003e).\u003c\/li\u003e\n    \u003cli\u003e\n\u003cstrong\u003eBottle = 30 days\u003c\/strong\u003e at 1 capsule daily. The cardiometabolic biomarker timeline is 8–12 weeks; budget 3 bottles before your first re-test.\u003c\/li\u003e\n  \u003c\/ul\u003e\n  \u003cp style=\"margin-bottom:0;\"\u003e→ \u003ca href=\"\/he\/protocols\/how-to-take-it\" style=\"color:#9a5b3e;font-weight:600;\"\u003eFull protocol guide for the entire stack\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv class=\"th-footer-links\" style=\"margin-top:48px;padding-top:24px;border-top:1px solid #e0d5c8;\"\u003e\n  \u003ch3 style=\"margin-bottom:12px;\"\u003eHave a specific question?\u003c\/h3\u003e\n  \u003cp style=\"margin:0 0 16px;\"\u003e→ \u003ca href=\"\/he\/pages\/faq\" style=\"color:#9a5b3e;\"\u003eFAQ — 20 most common questions\u003c\/a\u003e covers shipping, kashrut, drug interactions, refunds, dosing.\u003c\/p\u003e\n  \u003cp style=\"margin:0 0 16px;\"\u003e→ \u003ca href=\"\/he\/pages\/coa\" style=\"color:#9a5b3e;\"\u003eLab reports for every batch\u003c\/a\u003e — verifiable third-party COAs.\u003c\/p\u003e\n  \u003cp style=\"margin:0;\"\u003e→ Or just \u003ca href=\"mailto:kat@truehealthprotocol.health\" style=\"color:#9a5b3e;\"\u003eemail me directly\u003c\/a\u003e. I respond within 24 hours.\u003c\/p\u003e\n\u003c\/div\u003e\n","brand":"True Health Protocol","offers":[{"title":"Default Title","offer_id":47696174940378,"sku":"THP-RESV-600-60","price":29.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0814\/5158\/1658\/files\/resveratrol_02.jpg?v=1774728960","url":"https:\/\/truehealthprotocol.health\/he\/products\/resveratrol-600mg-60-capsules-30-day-supply","provider":"True Health Protocol","version":"1.0","type":"link"}